Alnylam Pharmaceuticals (United States)
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Alnylam Pharmaceuticals (United States), United States, covering academic research published from 2003 to 2023. Read More.
Open Access Percentage
62%
Total
Publications
783
Total Open
Publications
488
Total
Citations
66K
Open Access
Percentage
62%
Total
Publications
783
Total Open
Publications
488
Total
Citations
66K
Breakdown
Publisher Open
17%
Both
34%
Other Platform Open
11%
Closed
38%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 30%
119
Hybrid 32%
129
No Guarantees 38%
151
Other Platform Open
Domain 81%
286
Institution 26%
90
Preprint 14%
48
Other Internet 10%
35
Public 9%
30
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 284 |
Europe PMC | Domain | 204 |
bioRxiv | Preprint | 27 |
University College London - UCL Discovery | Institution | 25 |
Semantic Scholar | Public | 21 |
DOI | Other Internet | 17 |
Massachusetts Institute of Technology - DSpace@MIT | Institution | 15 |
Harvard University - Digital Access to Scholarship at Harvard (DASH) | Institution | 13 |
Figshare | Public | 13 |
Research Square | Preprint | 12 |